Combined Modality Therapy for Stage I-II DLBCL

Standard therapy for stage I-II diffuse large B-cell lymphoma (DLBCL) is combined modality therapy (CMT): anthracycline-based chemotherapy with radiotherapy (RT). The addition of rituximab (R) to CMT has improved the outcomes in all patients with DLBCL. At the same time we witnessed a change in RT planning with computed tomography-planned RT based on targeting initial disease extent only. To assess the impact of these changes in practice on the pattern of failure, we examined the outcomes in  recently treated cohort of patients with localized DLBCL, pre- and post-R era.

To download the full presentation of findings click the link below:

Combined Modality Therapy for Stage I-II DLBCL
Share on